Lead Product(s): ADX10061
Therapeutic Area: Neurology Product Name: ADX10061
Highest Development Status: Discovery Product Type: Small molecule
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 27, 2020
CHF600K Innosuisse grant will support SIB's computational approaches to identify new therapeutic indications for ADX10061, a potent and selective dopamine D1 receptor antagonist.